食品伙伴網(wǎng)訊 據(jù)國外食品類網(wǎng)站消息，2012年康尼格拉食品公司向美國FDA提交申請，F(xiàn)DA發(fā)表結論認為，非常有限的科學證據(jù)會支持全谷物與降低二型糖尿病風險之間的關系，因此擬限制性批準該健康聲稱，以避免誤導消費者。

    康尼格拉食品公司表示，雖然對FDA的評定有些失望，但是仍認為此舉具有里程碑意義，并表示不會重新提交申請書。

    Qualified health claims enable firms to talk about a relationship between a substance and disease where the supporting science fails to meet the FDA's 'significant scientific agreement' standard, but the claims are 'qualified' in such a way as to not mislead consumers.

    While the qualification often comes in the form of a far-from-consumer-friendly disclaimer, many observers believe the claims are still better than nothing.

    As a result, the FDA will consider exercising its enforcement discretion for the following qualified health claims:

    'Whole grains may reduce the risk of type 2 diabetes, although the FDA has concluded that there is very limited scientific evidence for this claim.'

    OR: 'Whole grains may reduce the risk of type 2 diabetes. FDA has concluded that there is very limited scientific evidence for this claim.'

    In its petition, ConAgra had suggested the following wording: 'Scientific evidence suggests, but does not prove, that diets low in saturated fat and cholesterol that include three servings （48g） of whole grains per day may reduce the risk of diabetes mellitus type 2.'

    原文鏈接：<http://www.foodnavigator-usa.com/Regulation/FDA-permits-qualified-health-claim-about-whole-grains-and-type-2-diabetes-but-is-the-wording-so-qualified-no-one-will-use-it>